These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36845991)

  • 1. Development of a computerized adaptive substance use disorder scale for screening, measurement and diagnosis - The CAT-SUD-E.
    Hulvershorn LA; Adams ZW; Smoker MP; Aalsma MC; Gibbons RD
    Drug Alcohol Depend Rep; 2022 Jun; 3():100047. PubMed ID: 36845991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a computerized adaptive substance use disorder scale for screening and measurement: the CAT-SUD.
    Gibbons RD; Alegria M; Markle S; Fuentes L; Zhang L; Carmona R; Collazos F; Wang Y; Baca-García E
    Addiction; 2020 Jul; 115(7):1382-1394. PubMed ID: 31943486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys.
    Degenhardt L; Bharat C; Bruno R; Glantz MD; Sampson NA; Lago L; Aguilar-Gaxiola S; Alonso J; Andrade LH; Bunting B; Caldas-de-Almeida JM; Cia AH; Gureje O; Karam EG; Khalaf M; McGrath JJ; Moskalewicz J; Lee S; Mneimneh Z; Navarro-Mateu F; Sasu CC; Scott K; Torres Y; Poznyak V; Chatterji S; Kessler RC;
    Addiction; 2019 Mar; 114(3):534-552. PubMed ID: 30370636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Computerized Adaptive Test for Mental Health in Primary Care.
    Graham AK; Minc A; Staab E; Beiser DG; Gibbons RD; Laiteerapong N
    Ann Fam Med; 2019 Jan; 17(1):23-30. PubMed ID: 30670391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Test-retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview.
    Hasin D; Shmulewitz D; Stohl M; Greenstein E; Roncone S; Aharonovich E; Wall M
    Drug Alcohol Depend; 2020 Nov; 216():108294. PubMed ID: 33007702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substance use disorders in individuals with body dysmorphic disorder.
    Grant JE; Menard W; Pagano ME; Fay C; Phillips KA
    J Clin Psychiatry; 2005 Mar; 66(3):309-16; quiz 404-5. PubMed ID: 15766296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and Accurate Behavioral Health Diagnostic Screening: Initial Validation Study of a Web-Based, Self-Report Tool (the SAGE-SR).
    Brodey B; Purcell SE; Rhea K; Maier P; First M; Zweede L; Sinisterra M; Nunn MB; Austin MP; Brodey IS
    J Med Internet Res; 2018 Mar; 20(3):e108. PubMed ID: 29572204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and correlates of alcohol and other substance use disorders in young adulthood: A population-based study.
    Latvala A; Tuulio-Henriksson A; Perälä J; Saarni SI; Aalto-Setälä T; Aro H; Korhonen T; Koskinen S; Lönnqvist J; Kaprio J; Suvisaari J
    BMC Psychiatry; 2009 Nov; 9():73. PubMed ID: 19925643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of Computerized Adaptive Assessment Tools for the Measurement of Posttraumatic Stress Disorder Among US Military Veterans.
    Brenner LA; Betthauser LM; Penzenik M; Germain A; Li JJ; Chattopadhyay I; Frank E; Kupfer DJ; Gibbons RD
    JAMA Netw Open; 2021 Jul; 4(7):e2115707. PubMed ID: 34236411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Item Response Theory Analysis to Assess Dimensionality of Substance Use Disorder Abuse and Dependence Symptoms.
    Kirisci L; Tarter RE; Reynolds M; Vanyukov MM
    Int J Pers Cent Med; 2016; 6(4):260-273. PubMed ID: 28944002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater Prevalence of Proposed ICD-11 Alcohol and Cannabis Dependence Compared to ICD-10, DSM-IV, and DSM-5 in Treated Adolescents.
    Chung T; Cornelius J; Clark D; Martin C
    Alcohol Clin Exp Res; 2017 Sep; 41(9):1584-1592. PubMed ID: 28667763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
    McCabe SE; West BT; Strobbe S; Boyd CJ
    J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine Assessment of Symptoms of Substance Use Disorders in Primary Care: Prevalence and Severity of Reported Symptoms.
    Sayre M; Lapham GT; Lee AK; Oliver M; Bobb JF; Caldeiro RM; Bradley KA
    J Gen Intern Med; 2020 Apr; 35(4):1111-1119. PubMed ID: 31974903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample.
    Peer K; Rennert L; Lynch KG; Farrer L; Gelernter J; Kranzler HR
    Drug Alcohol Depend; 2013 Jan; 127(1-3):215-9. PubMed ID: 22884164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-observer reliability of DSM-5 substance use disorders.
    Denis CM; Gelernter J; Hart AB; Kranzler HR
    Drug Alcohol Depend; 2015 Aug; 153():229-35. PubMed ID: 26048641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders.
    Tsai J; Gu X
    Addict Sci Clin Pract; 2019 Mar; 14(1):9. PubMed ID: 30836991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple DSM-5 substance use disorders: A national study of US adults.
    McCabe SE; West BT; Jutkiewicz EM; Boyd CJ
    Hum Psychopharmacol; 2017 Sep; 32(5):. PubMed ID: 28750478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration.
    Williams EC; Fletcher OV; Frost MC; Harris AHS; Washington DL; Hoggatt KJ
    JAMA Netw Open; 2022 Jun; 5(6):e2219651. PubMed ID: 35771574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Costs of Substance Use Disorders in the US Employer-Sponsored Insurance Population.
    Li M; Peterson C; Xu L; Mikosz CA; Luo F
    JAMA Netw Open; 2023 Jan; 6(1):e2252378. PubMed ID: 36692881
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.